MX365403B - Peptides and methods of using same. - Google Patents

Peptides and methods of using same.

Info

Publication number
MX365403B
MX365403B MX2014007799A MX2014007799A MX365403B MX 365403 B MX365403 B MX 365403B MX 2014007799 A MX2014007799 A MX 2014007799A MX 2014007799 A MX2014007799 A MX 2014007799A MX 365403 B MX365403 B MX 365403B
Authority
MX
Mexico
Prior art keywords
peptides
methods
same
autoimmune
inflammatory
Prior art date
Application number
MX2014007799A
Other languages
Spanish (es)
Other versions
MX2014007799A (en
Inventor
Mogelsvang Soren
Gelber Cohava
Original Assignee
Serpin Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serpin Pharma Llc filed Critical Serpin Pharma Llc
Publication of MX2014007799A publication Critical patent/MX2014007799A/en
Publication of MX365403B publication Critical patent/MX365403B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
MX2014007799A 2012-01-09 2013-01-07 Peptides and methods of using same. MX365403B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584517P 2012-01-09 2012-01-09
US201261699571P 2012-09-11 2012-09-11
PCT/US2013/020498 WO2013106273A2 (en) 2012-01-09 2013-01-07 Peptides and methods of using same

Publications (2)

Publication Number Publication Date
MX2014007799A MX2014007799A (en) 2014-10-24
MX365403B true MX365403B (en) 2019-05-31

Family

ID=47595077

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007799A MX365403B (en) 2012-01-09 2013-01-07 Peptides and methods of using same.

Country Status (11)

Country Link
US (5) US9951104B2 (en)
EP (2) EP3381461B1 (en)
JP (1) JP6416627B2 (en)
AU (3) AU2013208293B2 (en)
CA (2) CA2859777C (en)
DK (2) DK3381461T3 (en)
ES (2) ES2871544T3 (en)
HK (1) HK1203161A1 (en)
IL (1) IL233481A0 (en)
MX (1) MX365403B (en)
WO (1) WO2013106273A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
EP4219534A3 (en) 2013-07-08 2023-09-27 The University of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders
AU2015317771A1 (en) * 2014-09-16 2017-04-06 Bioincept, Llc Compositions and methods for treating acute radiation syndrome
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016141350A1 (en) * 2015-03-04 2016-09-09 Microvention, Inc. Drug delivery device
CN113429455A (en) * 2015-08-28 2021-09-24 赛品制药有限责任公司 Methods for disease treatment
WO2017083433A1 (en) * 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019212031A1 (en) * 2018-05-02 2019-11-07 国立大学法人新潟大学 Peptide and use therefor
WO2022010939A2 (en) * 2020-07-06 2022-01-13 Serpin Pharma, Llc Peptides and methods of using the same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190891B (en) 1982-06-24 1988-02-24 Anic Spa METHOD FOR SOLID PHASE SYNTHESIS OF RETROINVERTED POLYPEPTIDES
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
FI81498C (en) 1987-01-13 1990-11-12 Biocon Oy SURGICAL MATERIAL OCH INSTRUMENT.
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
BR9306984A (en) 1992-08-27 1999-01-12 Deakin Res Ltd Peptide antigen analog of a native peptide antigen vaccine antibody process to vaccinate a host in need of this treatment kit diagnostic processes to prepare an antigen analog of a native peptide antigen to prepare a vaccine to analyze a sample for a peptide antigen native and to analyze a sample for an antibody
DE69331387T2 (en) 1992-09-10 2002-08-22 Childrens Medical Center BIODEGRADABLE POLYMER MATRICATES WITH DELAYED RELEASE OF LOCALANE AESTHETICS
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
WO1997014809A2 (en) 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
EP1071806B1 (en) 1998-04-24 2004-06-16 University of Florida Recombinant adeno-associated viral vector encoding alpha-1-antitrypsin for gene therapy
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US20070003518A1 (en) 2002-04-19 2007-01-04 Atkinson Mark A Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
JP2007504144A (en) 2003-08-26 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト Serine protease activity inhibitors and methods for their use in the treatment and composition of bacterial infections
EP2302393A1 (en) * 2004-05-21 2011-03-30 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
WO2007100695A2 (en) 2006-02-28 2007-09-07 Trustees Of Boston University Metabolic regulators and uses thereof
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
US20090203602A1 (en) * 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US8623830B2 (en) 2006-09-12 2014-01-07 Beth Israel Deaconess Medical Center, Inc. Compositions containing α-1-antitrypsin and methods for use
AU2008292913B2 (en) 2007-08-30 2014-06-05 Curedm Group Holdings, Llc Compositions and methods of using proislet peptides and analogs thereof
US8758761B2 (en) 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US7923253B2 (en) * 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
KR20160146242A (en) 2015-06-12 2016-12-21 현대자동차주식회사 Device and method for operating RCV of turbo engine

Also Published As

Publication number Publication date
EP3381461A1 (en) 2018-10-03
CA3077804A1 (en) 2013-07-18
AU2017258892B2 (en) 2019-11-14
US8975224B2 (en) 2015-03-10
US20170029465A9 (en) 2017-02-02
HK1203161A1 (en) 2015-10-23
EP2802338B1 (en) 2018-03-07
AU2013208293B2 (en) 2017-08-10
US20200017550A1 (en) 2020-01-16
ES2871544T3 (en) 2021-10-29
AU2019253814B2 (en) 2022-03-10
US10899797B2 (en) 2021-01-26
WO2013106273A2 (en) 2013-07-18
IL233481A0 (en) 2014-08-31
JP6416627B2 (en) 2018-10-31
AU2013208293A2 (en) 2016-01-28
DK2802338T3 (en) 2018-06-14
CA2859777A1 (en) 2013-07-18
AU2013208293A1 (en) 2014-06-26
CA2859777C (en) 2020-06-30
DK3381461T3 (en) 2021-05-17
US10214562B2 (en) 2019-02-26
AU2019253814A1 (en) 2019-11-14
US20150133375A1 (en) 2015-05-14
ES2676028T3 (en) 2018-07-16
JP2015504073A (en) 2015-02-05
WO2013106273A3 (en) 2013-12-19
CA3077804C (en) 2023-07-25
US20130274187A1 (en) 2013-10-17
BR112014016734A2 (en) 2020-10-27
AU2017258892A1 (en) 2017-11-30
MX2014007799A (en) 2014-10-24
US20210188912A1 (en) 2021-06-24
US9951104B2 (en) 2018-04-24
EP2802338A2 (en) 2014-11-19
EP3381461B1 (en) 2021-03-10
US20140378372A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
MX365403B (en) Peptides and methods of using same.
PH12014501844B1 (en) Peptidomimetic macrocycles
MX2013015311A (en) Pcsk9-binding polypeptides and methods of use.
MX2015012933A (en) Microarray for delivery of therapeutic agent and methods of use.
MX2013008390A (en) Preparation of metal-triazolate frameworks.
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
MX2013011479A (en) Anti-fgfr4 antibodies and methods of use.
MX2019013670A (en) Antibody and protein formulations.
MX356107B (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases.
MX2015012326A (en) Anti-crth2 antibodies and their use.
MX2015009105A (en) Solid solution compositions and use in chronic inflammation.
MX2014004022A (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
MX366804B (en) R-spondin translocations and methods using the same.
MY168032A (en) Warm-Cool Beauty Treatment Device
MX2014002053A (en) Anti-mcsp antibodies.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX359769B (en) Methods of decellularizing bone.
MX366317B (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
MX354303B (en) Anti-biotin antibodies and methods of use.
MX2016004802A (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses.
MX357675B (en) Anti-jagged anitbodies and methods of use.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2013023059A3 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases
MX363385B (en) Treatment of sickle cell disease and inflammatory conditions.
MX361773B (en) Tlr3 binding agents.

Legal Events

Date Code Title Description
FG Grant or registration